Take Action
Research Details
Vioxx: Too Risky for Merck?
Abstract
This case follows Merck's pharmaceutical product, Vioxx, from initial development to launch and subsequent withdrawal, and considers the decisions made at each stage by the Merck executives involved. The case concludes by examining the financial impact of the Vioxx withdrawal on the company and on the Merck stock value.
Type
Case
Author(s)
Mitchell A. Petersen, Rashmi Singhal
Date Published
01/01/2007
Discipline
Finance;Organizational Behavior
Key Concepts
Drug development, Drug development risk, Risk in pharmaceutical industry, Investment in drug development, Withdrawal of drugs from the market
Citations
Petersen, Mitchell A., and Rashmi Singhal. Vioxx: Too Risky for Merck?. Case 5-207-253 (KEL289).
PREVIEW or BUY